The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:

•  51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017:
  • Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery)
  • Glatect (glatiramer acetate): Used to treat relapsing-remitting multiple sclerosis
  • Keytruda (pembrolizumab): Used to treat non-small cell lung cancer (first line)
  • Kyleena (levonorgestrel): Used for the prevention of pregnancy
  • Opdivo (nivolumab): Used to treat squamous cell carcinoma of the head and neck (SCCHN)
  • Tagrisso (osimertinib): Used to treat locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after EGFR TKI therapy
• 170 joint negotiations have been completed with 2 files closed as agreements were not reached since the last update of August 31, 2017:
  • Campral (acamprosate calcium): Used for maintenance of alcohol abstinence
  • Otezla (apremilast): Used to treat moderate to severe plaque psoriasis
• 55 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with 1 new file added since the last update of August 31, 2017:
  • Truvada (emtricitabine/tenofovir disoproxil fumarate): Used for pre-exposure prophylaxis of HIV-1 infection
• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of August 31, 2017.

For more information, please consult the pCPA’s website.